Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448363) titled 'Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica' on Feb. 26.
Study Type: Observational [Patient Registry]
Primary Sponsor: Caja Costarricense de Seguro Social
Condition:
Atopic Dermatitis
Atopic Dermatitis (AD)
Atopic Dermatitis (Eczema)
Atopic Dermatitis Patients
Atopic Dermatitis / Eczema
Atopic Dermatitis, Unspecified
Intervention:
Drug: Abrocitinib
Drug: Upadacitinib
Drug: Baricitinib
Recruitment Status: Not recruiting
Date of First Enrollment: May 2026
Target Sample Size: 50
Countries of Recruitment:
Costa Rica
To know more, visit https://clinicaltrials.gov/study/NCT0744836...